Search

Your search keyword '"Cavazzini, F."' showing total 280 results

Search Constraints

Start Over You searched for: Author "Cavazzini, F." Remove constraint Author: "Cavazzini, F."
280 results on '"Cavazzini, F."'

Search Results

1. Differences among young adults, adults and elderly chronic myeloid leukemia patients

2. S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA

3. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME

4. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB

6. Differences among young adults, adults and elderly chronic myeloid leukemia patients

7. Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

8. Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays

16. PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS

17. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

19. LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE

20. Observational Study of CML Italian Patients Who Discontinued TKIs

23. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

24. Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: a Retrospective Analysis of 208 Italian Patients

25. TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA

27. VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY?

28. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations

29. CARDIOVASCULAR EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FIRST-LINE: AN ANALISYS OF THE GIMEMA CML WP

30. Proliferation centres in chronic lymphocytic leucemia: correlation with cytogenetic and clinicobiological features in 183 patients analyzed on tissue-microarrays

31. DECLINING ROLE OF DISEASE TRANSORMATION AS A CAUSE OF DEATH IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN EARLY CHRONIC PHASE: A LONG-TERM ANALYSIS BY THE GIMEMA CML WP

35. FRONTLINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH SEQUENTIAL ADMINISTRATION OF NILO- TINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY: A PHASE 2 MULTICENTRIC STUDY

36. Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study

38. EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS

39. TREATMENT OF PH+ CML IN EARLY CHRONIC PHASE WITH SEQUENTIAL ADMINISTRATION OF NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY: A GIMEMA PHASE 2 MULTICENTRIC STUDY

42. Socio-demographic and clinical determinants of patient-reported symptom severity in chronic myeloid leukemia survivors in treatment with imatinib over the long run

43. THE BCR-ABL FUSION TRANSCRIPT HAS A PROGNOSTIC IMPACT IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB IN EARLY CHRONIC PHASE: A GIMEMA CML WP ANALYSIS

44. LOW-DOSE IMATINIB IN VERY ELDERLY (> 75 YEARS) CML PATIENTS: IS IT ENOUGH?

47. SOCIO-DEMOGRAPHIC AND CLINICAL DETERMINANTS OF PATIENT- REPORTED SYMPTOM SEVERITY IN CHRONIC MYELOID LEUKEMIA SURVIVORS IN TREATMENT WITH IMATINIB OVER THE LONG RUN

48. LOW DOSE CONTINUOUS THERAPY WITH DASATINIB SIGNIFICANTLY IMPACT ON SURVIVAL OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML) RESISTANT OR INTOLERANT TO IMATINIB. RESULTS FROM A REAL LIFE-BASED ITALIAN MULTICENTER RETROSPECTIVE STUDY ON 114 UNSELECTED PATIENTS

50. IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY PATIENTS WITH IMATINIB-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA

Catalog

Books, media, physical & digital resources